{"id":35728,"date":"2026-07-16T17:29:26","date_gmt":"2026-07-16T11:59:26","guid":{"rendered":"https:\/\/www.delveinsight.com\/blog\/?p=35728"},"modified":"2026-07-16T17:29:28","modified_gmt":"2026-07-16T11:59:28","slug":"medtech-news-for-polytech-electrowire-neurolexiq","status":"publish","type":"post","link":"https:\/\/www.delveinsight.com\/blog\/medtech-news-for-polytech-electrowire-neurolexiq","title":{"rendered":"POLYTECH Announced Regulatory Clearance for Improvements to the Microthane Process; ElectroWire Medical Earns 510(k) Clearance for LightningWire\u2122 System; NeuroLexIQ Partners with Canary Speech to Introduce AI-Driven Voice Analysis for Injury Intake; BIOTRONIK Neuro Acquires Spinal Cord Stimulation Technology from Soin Neuroscience; Lakewood-Amedex Biotherapeutics Highlights Preclinical Safety Evidence Ahead of Nu-3 Gel Phase 2a Study; Cumulus Neuroscience Presents Evidence That Two-Minute Digital Test Enhances Alzheimer&#8217;s Trial Pre-enrichment"},"content":{"rendered":"<div id=\"ez-toc-container\" class=\"ez-toc-v2_0_85 counter-hierarchy ez-toc-counter ez-toc-white ez-toc-container-direction\">\n<p class=\"ez-toc-title\" style=\"cursor:inherit\">Table of Contents<\/p>\n<label for=\"ez-toc-cssicon-toggle-item-6a58f6d057dda\" class=\"ez-toc-cssicon-toggle-label\"><span class=\"\"><span class=\"eztoc-hide\" style=\"display:none;\">Toggle<\/span><span class=\"ez-toc-icon-toggle-span\"><svg style=\"fill: #999;color:#999\" xmlns=\"http:\/\/www.w3.org\/2000\/svg\" class=\"list-377408\" width=\"20px\" height=\"20px\" viewBox=\"0 0 24 24\" fill=\"none\"><path d=\"M6 6H4v2h2V6zm14 0H8v2h12V6zM4 11h2v2H4v-2zm16 0H8v2h12v-2zM4 16h2v2H4v-2zm16 0H8v2h12v-2z\" fill=\"currentColor\"><\/path><\/svg><svg style=\"fill: #999;color:#999\" class=\"arrow-unsorted-368013\" xmlns=\"http:\/\/www.w3.org\/2000\/svg\" width=\"10px\" height=\"10px\" viewBox=\"0 0 24 24\" version=\"1.2\" baseProfile=\"tiny\"><path d=\"M18.2 9.3l-6.2-6.3-6.2 6.3c-.2.2-.3.4-.3.7s.1.5.3.7c.2.2.4.3.7.3h11c.3 0 .5-.1.7-.3.2-.2.3-.5.3-.7s-.1-.5-.3-.7zM5.8 14.7l6.2 6.3 6.2-6.3c.2-.2.3-.5.3-.7s-.1-.5-.3-.7c-.2-.2-.4-.3-.7-.3h-11c-.3 0-.5.1-.7.3-.2.2-.3.5-.3.7s.1.5.3.7z\"\/><\/svg><\/span><\/span><\/label><input type=\"checkbox\"  id=\"ez-toc-cssicon-toggle-item-6a58f6d057dda\"  aria-label=\"Toggle\" \/><nav><ul class='ez-toc-list ez-toc-list-level-1 ' ><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-1\" href=\"https:\/\/www.delveinsight.com\/blog\/medtech-news-for-polytech-electrowire-neurolexiq\/#POLYTECH_Announced_the_Approval_of_an_Updated_Process_for_Microthane%C2%AE\" >POLYTECH Announced the Approval of an Updated Process for Microthane\u00ae&nbsp;<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-2\" href=\"https:\/\/www.delveinsight.com\/blog\/medtech-news-for-polytech-electrowire-neurolexiq\/#ElectroWire_Medical_Received_510k_Clearance_for_LightningWire%E2%84%A2_Transseptal_Puncture_System\" >ElectroWire Medical Received 510(k) Clearance for LightningWire\u2122 Transseptal Puncture System&nbsp;<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-3\" href=\"https:\/\/www.delveinsight.com\/blog\/medtech-news-for-polytech-electrowire-neurolexiq\/#NeuroLexIQ_and_Canary_Speech_Partnered_to_Bring_AI_Voice_Analysis_to_the_Personal_Injury_Intake_Process\" >NeuroLexIQ and Canary Speech Partnered to Bring AI Voice Analysis to the Personal Injury Intake Process&nbsp;<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-4\" href=\"https:\/\/www.delveinsight.com\/blog\/medtech-news-for-polytech-electrowire-neurolexiq\/#BIOTRONIK_Neuro_Acquired_Spinal_Cord_Stimulation_System_from_Soin_Neuroscience\" >BIOTRONIK Neuro Acquired Spinal Cord Stimulation System from Soin Neuroscience&nbsp;&nbsp;<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-5\" href=\"https:\/\/www.delveinsight.com\/blog\/medtech-news-for-polytech-electrowire-neurolexiq\/#Lakewood-Amedex_Biotherapeutics_Announced_the_Preclinical_Safety_Data_Supporting_Clinical_Dose_Selection_for_Upcoming_Phase_2a_Trial_of_Nu-3_Gel\" >Lakewood-Amedex Biotherapeutics Announced the Preclinical Safety Data Supporting Clinical Dose Selection for Upcoming Phase 2a Trial of Nu-3 Gel<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-6\" href=\"https:\/\/www.delveinsight.com\/blog\/medtech-news-for-polytech-electrowire-neurolexiq\/#Cumulus_Neuroscience_Presents_Data_at_AAIC_2026_Annual_Meeting_Showing_a_Two-Minute_Digital_Task_Matches_or_Outperforms_Clinical_Benchmarks_for_Alzheimers_Trial_Pre-enrichment\" >Cumulus Neuroscience Presents Data at AAIC 2026 Annual Meeting Showing a Two-Minute Digital Task Matches or Outperforms Clinical Benchmarks for Alzheimer&#8217;s Trial Pre-enrichment&nbsp;<\/a><\/li><\/ul><\/nav><\/div>\n\n<h2 class=\"wp-block-heading\" id=\"h-polytech-announced-the-approval-of-an-updated-process-for-microthane-nbsp\"><span class=\"ez-toc-section\" id=\"POLYTECH_Announced_the_Approval_of_an_Updated_Process_for_Microthane%C2%AE\"><\/span><strong>POLYTECH Announced the Approval of an Updated Process for Microthane\u00ae&nbsp;<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n\n\n\n<p>On 16 July 2026, POLYTECH Health &amp; Aesthetics announced the approval of its updated proprietary manufacturing process for Microthane\u00ae, its polyurethane-coated breast implant technology. The company stated that the revised process was developed following extensive technical and legal evaluations and was supported by an independent Freedom-to-Operate assessment. The approval enabled POLYTECH to proceed with the phased market introduction of the updated Microthane\u00ae technology while completing the required regulatory and market-specific implementation steps. This development strengthened the company&#8217;s position in the breast implant market by ensuring continued innovation, product availability, and support for both breast reconstruction and aesthetic augmentation procedures.<\/p>\n\n\n\n<p><em>&#8220;Innovation at POLYTECH is built on continuous research,&#8221; stated Prof. Dr. Karsten Hemmrich, POLYTECH&#8217;s CEO. &#8220;Microthane\u00ae reflects our long-term commitment to polyurethane technology, manufacturing excellence, and supporting surgeons with solutions that continue to evolve alongside clinical practice.&#8221;<\/em><\/p>\n\n\n\n<p>As per DelveInsight\u2019s \u201c<a href=\"https:\/\/www.delveinsight.com\/report-store\/breast-implants-market\"><strong>Breast Implants Market Report<\/strong><\/a>,\u201d The breast implants market was valued at <strong>USD 1.80 billion<\/strong> in 2023, growing at a <strong>CAGR of 7.00% <\/strong>during the forecast period from 2024 to 2030 to reach <strong>USD 2.70 billion<\/strong> by 2030. The breast implants market is experiencing significant growth due to the increasing instances of breast cancer, rising product development activities, a rise in breast reconstructive and cosmetic surgeries, and the availability of a wide variety of breast implants, which are acting as major factors contributing to the overall growth of the breast implants market during the forecast period from 2024 to 2030.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-electrowire-medical-received-510-k-clearance-for-lightningwire-transseptal-puncture-system-nbsp\"><span class=\"ez-toc-section\" id=\"ElectroWire_Medical_Received_510k_Clearance_for_LightningWire%E2%84%A2_Transseptal_Puncture_System\"><\/span><strong>ElectroWire Medical Received 510(k) Clearance for LightningWire\u2122 Transseptal Puncture System&nbsp;<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n\n\n\n<p>On 15 July 2026, ElectroWire Medical announced that it had received U.S. Food and Drug Administration (FDA) 510(k) clearance for its LightningWire\u2122 Transseptal Puncture System (TPS), marking a significant regulatory milestone for the company. The clearance authorized the commercialization of the device in the United States and expanded the range of transseptal access technologies available for physicians performing minimally invasive cardiac procedures.<\/p>\n\n\n\n<p>The LightningWire\u2122 Transseptal Puncture System was developed to facilitate safe, efficient, and controlled transseptal puncture, enabling clinicians to gain access to the left atrium during a variety of electrophysiology and structural heart interventions. The system integrated the puncture needle and guidewire into a single platform, simplifying the procedural workflow, reducing the number of device exchanges, and enhancing procedural precision. The technology was designed to improve physician control while minimizing procedural complexity during left-heart access procedures.<\/p>\n\n\n\n<p>The FDA&#8217;s determination that the device was substantially equivalent to legally marketed predicate devices validated the system&#8217;s safety and effectiveness for its intended clinical use. The regulatory clearance positioned ElectroWire Medical to introduce its innovative transseptal puncture technology to hospitals and cardiac centers across the United States, where demand for advanced access devices continues to increase alongside the growing adoption of catheter-based therapies for cardiac rhythm disorders and structural heart diseases.<\/p>\n\n\n\n<p><em>&#8220;Our CE Mark MDR certification for Triojection is another positive step towards expanding ozone\u2011oxygen injection use across the world,&#8221; said Dr. Kieran Murphy, Chief Medical Officer, Co\u2011Founder and Chairman of SpinaFX. &#8220;CE Mark gives us the ability to commercialize in Europe and Asia, while we pursue our FDA IDE trial in the U.S., the largest market in the world for intradiscal procedures. The potential impact on suffering patients and health systems is enormous.&#8221;<\/em><\/p>\n\n\n\n<p><em>&#8220;CE Mark MDR is an important valuation inflection point,&#8221; said John Soloninka, Chief Executive Officer of SpinaFX Medical Inc. &#8220;Not only does this give us access to the 27 EU member states, but also to 13 other international regions, including the UK, Switzerland, parts of the Middle East, South American and Asian markets, where CE Mark MDR is either accepted or facilitates registration. This gives SpinaFX the ability to generate revenue and ro<\/em>bust post\u2011market evidence as we pursue our FDA clinical trial in advance of a future PMA application.&#8221;<\/p>\n\n\n\n<p>As per DelveInsight\u2019s \u201c<a href=\"https:\/\/www.delveinsight.com\/report-store\/electrophysiology-diagnsotic-catheters-market\"><strong>Electrophysiology Catheters Market Report<\/strong><\/a>,\u201d The electrophysiology catheters market is estimated to grow at a <strong>CAGR of 6.73%<\/strong> during the forecast period from 2024 to 2030. The demand for electrophysiology catheters is primarily being boosted by the increasing prevalence of cardiovascular disorders around the globe. Additionally, the growing risk associated with cardiovascular disorders is another key factor that is contributing to the growth of the electrophysiology catheters market during the forecast period from 2024 to 2030.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-neurolexiq-and-canary-speech-partnered-to-bring-ai-voice-analysis-to-the-personal-injury-intake-process-nbsp\"><span class=\"ez-toc-section\" id=\"NeuroLexIQ_and_Canary_Speech_Partnered_to_Bring_AI_Voice_Analysis_to_the_Personal_Injury_Intake_Process\"><\/span><strong>NeuroLexIQ and Canary Speech Partnered to Bring AI Voice Analysis to the Personal Injury Intake Process&nbsp;<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n\n\n\n<p>On 15 July 2026, NeuroLexIQ announced that it had entered into a strategic partnership with Canary Speech to integrate artificial intelligence (AI)-powered voice analysis into the personal injury intake process. The collaboration combined NeuroLexIQ&#8217;s concussion assessment platform with Canary Speech&#8217;s proprietary vocal biomarker technology to enable the identification of potential brain injuries during an individual&#8217;s initial interaction with legal professionals. The initiative represented a significant advancement in the use of AI for objective neurological screening, allowing potential concussion cases to be identified before conventional medical evaluations were conducted.<\/p>\n\n\n\n<p>Under the partnership, Canary Speech&#8217;s AI technology was embedded into NeuroLexIQ&#8217;s Concussion Probability Report, where speech samples collected during the first client intake conversation were analyzed for subtle vocal biomarkers associated with mild traumatic brain injury (mTBI). The system evaluated changes in speech patterns that could indicate neurological impairment and generated an objective probability assessment for concussion. Individuals identified as having an elevated likelihood of brain injury were then directed for quantitative electroencephalography (qEEG) testing and independent neurological evaluation, creating a structured and evidence-based diagnostic pathway from the earliest stage of case intake.<\/p>\n\n\n\n<p>The companies stated that the integrated workflow addressed one of the major challenges in personal injury cases, where concussions and other mild brain injuries frequently remained undiagnosed or undocumented because symptoms could be subtle, delayed, or easily overlooked. By incorporating AI-driven voice biomarker analysis immediately after an incident was reported, the solution enabled attorneys and healthcare professionals to capture objective neurological indicators while they were still detectable. This approach strengthened the documentation process, improved clinical decision-making, and supported the development of litigation-ready medical evidence for brain injury claims.<\/p>\n\n\n\n<p>The collaboration also demonstrated the growing application of artificial intelligence beyond conventional healthcare environments by extending clinical-grade screening technologies into legal and insurance workflows. The integration of voice biomarker analysis with neurological testing reflected an emerging trend toward multimodal digital diagnostics, where AI tools complement traditional medical assessments to improve accuracy, efficiency, and accessibility. Through this partnership, both companies aimed to enhance early concussion detection, reduce the number of undiagnosed traumatic brain injuries, and improve outcomes for patients while providing legal professionals with more reliable and objective clinical evidence. A pilot implementation of the integrated solution was scheduled to begin in July 2026, supporting broader adoption of AI-enabled neurological assessment technologies across healthcare and legal ecosystems.<\/p>\n\n\n\n<p><em>&#8220;For the past decade, we&#8217;ve done the hard work of turning voice into a clinically meaningful signal,&#8221; said Henry O&#8217;Connell, CEO of Canary Speech. &#8220;In personal injury cases, timing is everything. Partnering with NeuroLexIQ lets us put that signal to work at the exact moment it can do the most good.&#8221;<\/em><\/p>\n\n\n\n<p><em>&#8220;By adding Canary Speech&#8217;s voice analysis to our intake process, we can objectively identify potential brain injuries from the first conversation and route the right cases for qEEG testing before symptoms fade and causation becomes harder to establish,&#8221; said Mark Slaughter, Founder &amp; CEO of NeuroLexIQ. &#8220;It&#8217;s a meaningful step forward for how our industry documents and supports these clients.&#8221;<\/em><\/p>\n\n\n\n<p>As per DelveInsight\u2019s \u201c<a href=\"https:\/\/www.delveinsight.com\/report-store\/artificial-intelligence-in-healthcare-market\"><strong>Artificial Intelligence (AI) in Healthcare Market Report<\/strong><\/a>,\u201d The global artificial intelligence in healthcare market is expected to increase from <strong>USD 40,809.25 million<\/strong> in 2025 to <strong>USD 861,636.63 million<\/strong> by 2034, growing at a <strong>CAGR of 40.40%<\/strong> during the forecast period from 2026 to 2034. The rising prevalence of chronic diseases is increasing the demand for continuous monitoring, early diagnosis, and personalized treatment, which AI-powered tools can efficiently support. At the same time, the accelerating adoption of AI and advanced analytics in healthcare is improving clinical decision-making, operational efficiency, and predictive insights across hospitals and research settings. The expansion of digital health, telemedicine, and remote patient monitoring is further generating large volumes of real-time patient data, enabling AI systems to deliver timely interventions and virtual care solutions. Additionally, advances in machine learning, deep learning, and generative AI are enhancing diagnostic accuracy, drug discovery, and personalized medicine capabilities. Collectively, these factors are significantly driving the growth and transformation of the AI in healthcare market.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-biotronik-neuro-acquired-spinal-cord-stimulation-system-from-soin-neuroscience-nbsp-nbsp\"><span class=\"ez-toc-section\" id=\"BIOTRONIK_Neuro_Acquired_Spinal_Cord_Stimulation_System_from_Soin_Neuroscience\"><\/span><strong>BIOTRONIK Neuro Acquired Spinal Cord Stimulation System from Soin Neuroscience&nbsp;&nbsp;<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n\n\n\n<p>On 15 July 2026, BIOTRONIK Neuro announced that it had acquired a portfolio of spinal cord stimulation (SCS) intellectual property from Soin Neuroscience, further expanding its neuromodulation technology platform for chronic pain treatment. The transaction included patents related to advanced spinal cord stimulation technologies and built upon the research collaboration established between the two companies in late 2025. Although the financial terms of the acquisition were not disclosed, the agreement represented a strategic step in BIOTRONIK Neuro&#8217;s efforts to strengthen its position in the rapidly evolving spinal cord stimulation market.<\/p>\n\n\n\n<p>The acquired intellectual property encompassed a broad range of innovations, including novel spinal cord stimulation waveform designs, adaptive programming technologies, and the application of artificial intelligence (AI) and machine learning algorithms to neuromodulation therapy. These technologies were developed to enhance the personalization of spinal cord stimulation by continuously adapting therapy parameters according to individual patient responses. BIOTRONIK Neuro stated that the acquired patents would support the future development of its next-generation spinal cord stimulation platform, enabling more precise, data-driven, and patient-specific chronic pain therapies.<\/p>\n\n\n\n<p>The acquisition followed a research collaboration initiated by BIOTRONIK Neuro and Soin Neuroscience in December 2025, during which both organizations evaluated proprietary stimulation waveforms and personalized programming strategies using BIOTRONIK Neuro&#8217;s Prospera\u2122 Spinal Cord Stimulation System. The successful collaboration established the scientific and technological foundation for the acquisition, allowing BIOTRONIK Neuro to integrate Soin Neuroscience&#8217;s proprietary technologies into its expanding neuromodulation portfolio. The company expected the combined technologies to improve programming flexibility, adaptive stimulation capabilities, and long-term therapeutic outcomes for patients suffering from chronic pain conditions.<\/p>\n\n\n\n<p>Soin Neuroscience confirmed that it would continue operating as an independent medical technology company following the transaction. The acquisition was limited exclusively to the intellectual property associated with the spinal cord stimulation program, while the company&#8217;s remaining research activities, product development initiatives, clinical studies, and business operations remained unaffected. This arrangement allowed Soin Neuroscience to continue advancing additional pain management technologies while enabling BIOTRONIK Neuro to commercialize and further develop the acquired spinal cord stimulation innovations on a global scale.<\/p>\n\n\n\n<p>The acquisition significantly enhanced BIOTRONIK Neuro&#8217;s capabilities in developing advanced neuromodulation therapies by adding technologies focused on adaptive stimulation, intelligent waveform optimization, and AI-enabled programming to its existing platform. The integration of these innovations aligned with the company&#8217;s long-term strategy of delivering personalized, non-opioid chronic pain treatments through intelligent spinal cord stimulation systems. The transaction also highlighted the increasing importance of strategic acquisitions and intellectual property consolidation within the neuromodulation industry, as medical device manufacturers continue investing in innovative technologies to improve clinical outcomes, expand treatment options for chronic pain patients, and strengthen their competitive positions in the global spinal cord stimulation market.<\/p>\n\n\n\n<p><em>&#8220;Spinal cord stimulation has helped countless patients manage chronic pain without relying on opioids, but there is still enormous room to make the therapy smarter, more personalized, and dynamic,&#8221; said Dr. Soin. &#8220;BIOTRONIK Neuro has the scale, engineering depth, and commitment to neuromodulation to take these technologies further than we could on our own. This agreement lets that work continue inside an organization built to bring it to patients at scale. I am also grateful to Dr Eric Schepis, PhD, whose brilliance, conceptual designs, and co-inventorship on a portion of our patents helped pave the way.&#8221;<\/em><\/p>\n\n\n\n<p>According to DelveInsight\u2019s \u201c<a href=\"https:\/\/www.delveinsight.com\/report-store\/spinal-cord-stimulator-market\"><strong>Spinal Cord Stimulators Market Report<\/strong><\/a>\u201d, the Global Spinal Cord Stimulator Market Size is expected to increase from <strong>~USD 3437 million<\/strong> in 2024 to <strong>~USD 7243.98 million<\/strong> by 2032, growing at a <strong>CAGR of 9.83%<\/strong> during the forecast period from 2025 to 2032. The spinal cord stimulator market is experiencing significant growth due to the increasing number of patients suffering from chronic pain and neuropathic pain, particularly in areas such as the shoulders, legs, and knees. Moreover, degenerative spine conditions, such as Diabetic Neuropathy, spinal cord injury, and Failed Back Surgery Syndrome, among others, are other contributing factors for market growth. Additionally, favorable government regulations have played a crucial role in accelerating the commercialization and launch of advanced spinal cord stimulation devices. The rising geriatric population, which is more susceptible to chronic and neuropathic conditions, is also contributing to market expansion. These factors, collectively, are expected to propel the growth of the spinal cord stimulator market throughout the forecast period from 2025 to 2032.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-lakewood-amedex-biotherapeutics-announced-the-preclinical-safety-data-supporting-clinical-dose-selection-for-upcoming-phase-2a-trial-of-nu-3-gel\"><span class=\"ez-toc-section\" id=\"Lakewood-Amedex_Biotherapeutics_Announced_the_Preclinical_Safety_Data_Supporting_Clinical_Dose_Selection_for_Upcoming_Phase_2a_Trial_of_Nu-3_Gel\"><\/span><strong>Lakewood-Amedex Biotherapeutics Announced the Preclinical Safety Data Supporting Clinical Dose Selection for Upcoming Phase 2a Trial of Nu-3 Gel<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n\n\n\n<p>On 15 July 2026, Lakewood-Amedex Biotherapeutics announced positive preclinical safety results for its lead investigational therapy, Nu-3 Gel, providing critical evidence to support dose selection for the company&#8217;s upcoming Phase 2a clinical trial in patients with infected diabetic foot ulcers (iDFUs). The study demonstrated that Nu-3 Gel was well tolerated at dose levels exceeding those planned for clinical evaluation, representing an important milestone in the advancement of the company&#8217;s novel Bisphosphocin\u00ae antimicrobial platform. The successful completion of the safety assessment strengthened the scientific foundation for initiating human studies and reinforced the therapeutic potential of Nu-3 as a topical treatment for chronic wound infections.<\/p>\n\n\n\n<p>The FDA-required preclinical safety study evaluated the local and systemic safety profile of Nu-3 Gel across multiple dose levels. Results showed that systemic exposure to the investigational therapy remained low despite administration at concentrations higher than those selected for the Phase 2a trial. In addition, the study confirmed that the gel did not interfere with normal wound-healing processes, an important consideration for therapies intended to treat infected diabetic foot ulcers where infection control and tissue repair must occur simultaneously. These findings provided strong support for advancing the product into clinical development while establishing an appropriate therapeutic window for dose selection.<\/p>\n\n\n\n<p>Based on the preclinical findings, Lakewood-Amedex finalized the dose strategy for the upcoming Phase 2a proof-of-concept study, which was designed to evaluate three concentrations of Nu-3 Gel, 2%, 5%, and 10%, in patients with mildly infected diabetic foot ulcers. The clinical trial was planned to assess both the safety and antimicrobial efficacy of the topical therapy while identifying the optimal dose for subsequent Phase 2b development. The study was expected to generate important clinical evidence regarding the product&#8217;s ability to reduce infection and improve outcomes in patients with diabetic foot ulcers, a condition associated with substantial morbidity, healthcare costs, and risk of lower-limb amputation.<\/p>\n\n\n\n<p>Nu-3 Gel was developed using Lakewood-Amedex&#8217;s proprietary Bisphosphocin\u00ae antimicrobial technology, a novel class of broad-spectrum agents designed to rapidly eliminate pathogenic bacteria, including antibiotic-resistant organisms and biofilms commonly found in chronic wounds. Unlike conventional antibiotics, the Bisphosphocin\u00ae platform was intended to reduce the potential for antimicrobial resistance while maintaining potent activity against a broad range of clinically significant pathogens. The company believed that this differentiated mechanism of action could address a major unmet need in the treatment of diabetic foot infections, where increasing antibiotic resistance continues to complicate patient management and limit therapeutic options.<\/p>\n\n\n\n<p>The announcement represented a significant advancement in Lakewood-Amedex Biotherapeutics&#8217; clinical development program and highlighted the growing industry focus on innovative antimicrobial therapies for chronic wound management. By successfully completing the required safety evaluations and selecting appropriate clinical doses, the company moved closer to initiating its Phase 2a trial and advancing a potential new treatment option for infected diabetic foot ulcers. The progress also underscored continued investment in next-generation topical antimicrobial therapies that aim to improve infection control, preserve wound healing, reduce dependence on systemic antibiotics, and address the global challenge of antimicrobial resistance.<\/p>\n\n\n\n<p><em>&#8220;Based on the preclinical data, including the safety study, the gel formulation of Nu-3 has the potential to be uniquely suited for the treatment of infected diabetic foot ulcers with broad-spectrum efficacy, fast-acting antimicrobial activity, as well as activity against highly resistant bacterial strains and complex biofilms,&#8221; stated Thomas Balzer, M.D., Ph.D., Chief Medical Officer of Lakewood-Amedex Biotherapeutics. &#8220;The selected concentrations are expected to provide sufficient dose-response information both for the antimicrobial activity in patients as well as safety and tolerability of Nu-3, as a topical formulation that ensures a localized therapeutic impact with a low risk of systemic side effects.&#8221;<\/em><\/p>\n\n\n\n<p>According to DelveInsight\u2019s \u201d<a href=\"https:\/\/www.delveinsight.com\/report-store\/diabetic-foot-ulcer-treatment-market\"><strong>Diabetic Foot Ulcer Treatment Market Report<\/strong><\/a>,\u201d The global diabetic foot ulcer treatment market is estimated to grow at a <strong>CAGR of 7.31% <\/strong>during the forecast period from 2024 to 2030. The demand for diabetic foot ulcer treatment is primarily being boosted owing to key factors such as the increasing prevalence of diabetic foot ulcers, increasing risk factors such as diabetes, and others associated with the development of diabetic foot ulcers, the growing technological advancements along with research and development activities, among other factors are expected to create a positive impact on the market growth during the forecast period from 2024 to 2030.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-cumulus-neuroscience-presents-data-at-aaic-2026-annual-meeting-showing-a-two-minute-digital-task-matches-or-outperforms-clinical-benchmarks-for-alzheimer-s-trial-pre-enrichment-nbsp\"><span class=\"ez-toc-section\" id=\"Cumulus_Neuroscience_Presents_Data_at_AAIC_2026_Annual_Meeting_Showing_a_Two-Minute_Digital_Task_Matches_or_Outperforms_Clinical_Benchmarks_for_Alzheimers_Trial_Pre-enrichment\"><\/span><strong>Cumulus Neuroscience Presents Data at AAIC 2026 Annual Meeting Showing a Two-Minute Digital Task Matches or Outperforms Clinical Benchmarks for Alzheimer&#8217;s Trial Pre-enrichment&nbsp;<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n\n\n\n<p>On 15 July 2026, Cumulus Neuroscience announced that it had presented new clinical data at the Alzheimer&#8217;s Association International Conference (AAIC) 2026 demonstrating that its Symbol Swap digital cognitive assessment matched or outperformed established clinical benchmarks for Alzheimer&#8217;s disease trial pre-enrichment. The findings highlighted the potential of the company&#8217;s two-minute tablet-based assessment to identify individuals who were most likely to exhibit Alzheimer&#8217;s disease pathology before undergoing more expensive and invasive biomarker testing. The presentation reinforced the growing role of digital cognitive technologies in improving the efficiency of Alzheimer&#8217;s clinical trial recruitment and patient screening.<\/p>\n\n\n\n<p>The data were generated from three independent clinical studies involving approximately 1,280 participants across both at-home and in-clinic settings. Researchers compared the performance of Symbol Swap against widely used cognitive assessment tools, including the Alzheimer&#8217;s Disease Assessment Scale-Cognitive Subscale (ADAS-Cog), the Mini-Mental State Examination (MMSE), and the Montreal Cognitive Assessment (MoCA). The results demonstrated that the digital task consistently matched or exceeded the ability of these traditional assessments to distinguish cognitively healthy individuals from those with mild cognitive impairment and Alzheimer&#8217;s disease, despite requiring only two minutes to complete without clinician supervision.<\/p>\n\n\n\n<p>The study also demonstrated that Symbol Swap successfully identified subtle cognitive changes associated with Alzheimer&#8217;s pathology in individuals who remained clinically unimpaired on conventional cognitive tests. Investigators observed a strong association between performance on the digital task and plasma phosphorylated tau-217 (pTau-217), an established biomarker of Alzheimer&#8217;s disease. These findings suggested that the digital assessment could serve as an effective pre-screening tool to identify individuals with a higher probability of amyloid or tau pathology, allowing sponsors to prioritize candidates for subsequent blood tests, PET imaging, or cerebrospinal fluid analyses while reducing unnecessary biomarker testing.<\/p>\n\n\n\n<p>Cumulus Neuroscience stated that the Symbol Swap assessment formed part of its NeuLogiq\u00ae digital neuroscience platform, which was designed to enable remote, objective, and scalable cognitive monitoring throughout neurological clinical trials. By automating cognitive assessment and eliminating the need for lengthy clinician-administered evaluations during initial screening, the platform was expected to shorten recruitment timelines, lower operational costs, and improve participant selection for Alzheimer&#8217;s disease studies. The technology also supported decentralized clinical trial models by allowing patients to complete standardized assessments remotely while maintaining data consistency and quality.<\/p>\n\n\n\n<p>The presentation underscored the increasing adoption of digital biomarkers and artificial intelligence-enabled cognitive assessment technologies within Alzheimer&#8217;s disease research. As pharmaceutical companies continued developing disease-modifying therapies requiring biomarker-confirmed patient populations, rapid digital pre-enrichment tools became increasingly important for overcoming high screening failure rates and accelerating clinical development. Cumulus Neuroscience&#8217;s findings demonstrated how brief, digitally administered cognitive assessments could complement traditional diagnostic approaches, improve clinical trial efficiency, and support the broader transition toward data-driven, patient-centric neuroscience research and precision medicine.<\/p>\n\n\n\n<p><em>&#8220;It is striking that a two-minute, patient-friendly task can match or beat assessments that take a trained clinician 10 to 45 minutes to administer,&nbsp; and that it picks up Alzheimer&#8217;s pathology even in study participants who look cognitively normal on standard tests,&#8221; said Brian Murphy, PhD, Cumulus Co-Founder and CSO. &#8220;This data confirms that Symbol Swap may be a powerful first-line filter, preceding plasma biomarkers or feeding a multimodal composite. We are grateful to all the study participants and research collaborators who made these important findings possible.&#8221;<\/em><\/p>\n\n\n\n<p>According to DelveInsight\u2019s \u201c<a href=\"https:\/\/www.delveinsight.com\/report-store\/alzheimers-disease-diagnostic-market\"><strong>Alzheimer\u2019s Disease Diagnostic Market Report<\/strong><\/a>,\u201d the global Alzheimer\u2019s disease (AD) diagnostic market will grow at a<strong> CAGR of 10.97%<\/strong> during the forecast period from 2024 to 2030. The Alzheimer\u2019s disease (AD) diagnostic market is observing an optimistic market growth due to factors such as a rise in the regulatory approvals for Alzheimer\u2019s disease (AD) diagnostics across the globe. Further, the rising prevalence of head injuries owing to accidents, workplace injuries, and others, and the rise in the geriatric population will increase the prevalence of Alzheimer&#8217;s disease, thereby increasing the demand for Alzheimer&#8217;s disease diagnostic devices across the globe. Additionally, the increasing research and development of novel biomarkers, the presence of key players in the market, increasing product launches and approvals, and others will create a requirement for Alzheimer&#8217;s disease diagnostics in the upcoming years. Therefore, the market for Alzheimer\u2019s disease (AD) diagnostics is estimated to grow at a substantial CAGR during the forecast period from 2024 to 2030.<\/p>\n","protected":false},"excerpt":{"rendered":"<p>POLYTECH Announced the Approval of an Updated Process for Microthane\u00ae&nbsp; On 16 July 2026, POLYTECH Health &amp; Aesthetics announced the approval of its updated proprietary manufacturing process for Microthane\u00ae, its polyurethane-coated breast implant technology. The company stated that the revised process was developed following extensive technical and legal evaluations and was supported by an independent [&hellip;]<\/p>\n","protected":false},"author":14,"featured_media":35730,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"_editorskit_title_hidden":false,"_editorskit_reading_time":0,"_editorskit_is_block_options_detached":false,"_editorskit_block_options_position":"{}","advgb_blocks_editor_width":"","advgb_blocks_columns_visual_guide":"","footnotes":""},"categories":[32],"tags":[18113,20820,20291,22092,23048,17021,16975,19033],"industry":[17226],"therapeutic_areas":[17245],"class_list":["post-35728","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-notizia","tag-ai-in-healthcare","tag-alzheimers-disease-diagnostic","tag-breast-implants","tag-diabetic-foot-ulcer-treatment","tag-electrophysiology-catheters","tag-medical-devices-market","tag-medtech-market","tag-spinal-cord-stimulators","industry-medical-devices","therapeutic_areas-neurology"],"acf":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v27.9 (Yoast SEO v27.9) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>MedTech News | POLYTECH, ElectroWire Medical, NeuroLexIQ<\/title>\n<meta name=\"description\" content=\"POLYTECH\u2019s Microthane; ElectroWire Medical\u2019s LightningWire Transseptal Puncture System; BIOTRONIK Neuro\u2019s Spinal Cord Stimulation System\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.delveinsight.com\/blog\/medtech-news-for-polytech-electrowire-neurolexiq\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"MedTech News | POLYTECH, ElectroWire Medical, NeuroLexIQ\" \/>\n<meta property=\"og:description\" content=\"POLYTECH\u2019s Microthane; ElectroWire Medical\u2019s LightningWire Transseptal Puncture System; BIOTRONIK Neuro\u2019s Spinal Cord Stimulation System\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.delveinsight.com\/blog\/medtech-news-for-polytech-electrowire-neurolexiq\" \/>\n<meta property=\"og:site_name\" content=\"DelveInsight Business Research\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/DelveInsight-1423323754607782\/\" \/>\n<meta property=\"article:published_time\" content=\"2026-07-16T11:59:26+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2026-07-16T11:59:28+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.delveinsight.com\/blog\/wp-content\/uploads\/2026\/07\/medtech-news-for-polytech-electrowire-neurolexiq.webp\" \/>\n\t<meta property=\"og:image:width\" content=\"772\" \/>\n\t<meta property=\"og:image:height\" content=\"482\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/webp\" \/>\n<meta name=\"author\" content=\"Sandeep Joshi\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:creator\" content=\"@DelveInsight\" \/>\n<meta name=\"twitter:site\" content=\"@DelveInsight\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Sandeep Joshi\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"16 minutes\" \/>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"MedTech News | POLYTECH, ElectroWire Medical, NeuroLexIQ","description":"POLYTECH\u2019s Microthane; ElectroWire Medical\u2019s LightningWire Transseptal Puncture System; BIOTRONIK Neuro\u2019s Spinal Cord Stimulation System","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.delveinsight.com\/blog\/medtech-news-for-polytech-electrowire-neurolexiq","og_locale":"en_US","og_type":"article","og_title":"MedTech News | POLYTECH, ElectroWire Medical, NeuroLexIQ","og_description":"POLYTECH\u2019s Microthane; ElectroWire Medical\u2019s LightningWire Transseptal Puncture System; BIOTRONIK Neuro\u2019s Spinal Cord Stimulation System","og_url":"https:\/\/www.delveinsight.com\/blog\/medtech-news-for-polytech-electrowire-neurolexiq","og_site_name":"DelveInsight Business Research","article_publisher":"https:\/\/www.facebook.com\/DelveInsight-1423323754607782\/","article_published_time":"2026-07-16T11:59:26+00:00","article_modified_time":"2026-07-16T11:59:28+00:00","og_image":[{"width":772,"height":482,"url":"https:\/\/www.delveinsight.com\/blog\/wp-content\/uploads\/2026\/07\/medtech-news-for-polytech-electrowire-neurolexiq.webp","type":"image\/webp"}],"author":"Sandeep Joshi","twitter_card":"summary_large_image","twitter_creator":"@DelveInsight","twitter_site":"@DelveInsight","twitter_misc":{"Written by":"Sandeep Joshi","Est. reading time":"16 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.delveinsight.com\/blog\/medtech-news-for-polytech-electrowire-neurolexiq#article","isPartOf":{"@id":"https:\/\/www.delveinsight.com\/blog\/medtech-news-for-polytech-electrowire-neurolexiq"},"author":{"name":"Sandeep Joshi","@id":"https:\/\/www.delveinsight.com\/blog\/#\/schema\/person\/f1eefd8dd4afdb0617d6166f8b301e0a"},"headline":"POLYTECH Announced Regulatory Clearance for Improvements to the Microthane Process; ElectroWire Medical Earns 510(k) Clearance for LightningWire\u2122 System; NeuroLexIQ Partners with Canary Speech to Introduce AI-Driven Voice Analysis for Injury Intake; BIOTRONIK Neuro Acquires Spinal Cord Stimulation Technology from Soin Neuroscience; Lakewood-Amedex Biotherapeutics Highlights Preclinical Safety Evidence Ahead of Nu-3 Gel Phase 2a Study; Cumulus Neuroscience Presents Evidence That Two-Minute Digital Test Enhances Alzheimer&#8217;s Trial Pre-enrichment","datePublished":"2026-07-16T11:59:26+00:00","dateModified":"2026-07-16T11:59:28+00:00","mainEntityOfPage":{"@id":"https:\/\/www.delveinsight.com\/blog\/medtech-news-for-polytech-electrowire-neurolexiq"},"wordCount":3602,"image":{"@id":"https:\/\/www.delveinsight.com\/blog\/medtech-news-for-polytech-electrowire-neurolexiq#primaryimage"},"thumbnailUrl":"https:\/\/www.delveinsight.com\/blog\/wp-content\/uploads\/2026\/07\/medtech-news-for-polytech-electrowire-neurolexiq.webp","keywords":["AI In Healthcare","Alzheimer\u2019s Disease Diagnostic","Breast Implants","Diabetic Foot Ulcer Treatment","Electrophysiology Catheters","Medical Devices Market","MedTech Market","Spinal Cord Stimulators"],"articleSection":["Notizia - Recent Pharma, Healthcare and Biotech Happenings"],"inLanguage":"en-US","copyrightYear":"2026","copyrightHolder":{"@id":"https:\/\/www.delveinsight.com\/blog\/#organization"}},{"@type":"WebPage","@id":"https:\/\/www.delveinsight.com\/blog\/medtech-news-for-polytech-electrowire-neurolexiq","url":"https:\/\/www.delveinsight.com\/blog\/medtech-news-for-polytech-electrowire-neurolexiq","name":"MedTech News | POLYTECH, ElectroWire Medical, NeuroLexIQ","isPartOf":{"@id":"https:\/\/www.delveinsight.com\/blog\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.delveinsight.com\/blog\/medtech-news-for-polytech-electrowire-neurolexiq#primaryimage"},"image":{"@id":"https:\/\/www.delveinsight.com\/blog\/medtech-news-for-polytech-electrowire-neurolexiq#primaryimage"},"thumbnailUrl":"https:\/\/www.delveinsight.com\/blog\/wp-content\/uploads\/2026\/07\/medtech-news-for-polytech-electrowire-neurolexiq.webp","datePublished":"2026-07-16T11:59:26+00:00","dateModified":"2026-07-16T11:59:28+00:00","author":{"@id":"https:\/\/www.delveinsight.com\/blog\/#\/schema\/person\/f1eefd8dd4afdb0617d6166f8b301e0a"},"description":"POLYTECH\u2019s Microthane; ElectroWire Medical\u2019s LightningWire Transseptal Puncture System; BIOTRONIK Neuro\u2019s Spinal Cord Stimulation System","inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.delveinsight.com\/blog\/medtech-news-for-polytech-electrowire-neurolexiq"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.delveinsight.com\/blog\/medtech-news-for-polytech-electrowire-neurolexiq#primaryimage","url":"https:\/\/www.delveinsight.com\/blog\/wp-content\/uploads\/2026\/07\/medtech-news-for-polytech-electrowire-neurolexiq.webp","contentUrl":"https:\/\/www.delveinsight.com\/blog\/wp-content\/uploads\/2026\/07\/medtech-news-for-polytech-electrowire-neurolexiq.webp","width":772,"height":482,"caption":"medtech-news-for-polytech-electrowire-neurolexiq"},{"@type":"WebSite","@id":"https:\/\/www.delveinsight.com\/blog\/#website","url":"https:\/\/www.delveinsight.com\/blog\/","name":"DelveInsight Business Research","description":"Blog","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.delveinsight.com\/blog\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.delveinsight.com\/blog\/#\/schema\/person\/f1eefd8dd4afdb0617d6166f8b301e0a","name":"Sandeep Joshi","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/7676451175fe155887a18ffb50e674b270d87436a3fc34ca206f86921cddf4cd?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/7676451175fe155887a18ffb50e674b270d87436a3fc34ca206f86921cddf4cd?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/7676451175fe155887a18ffb50e674b270d87436a3fc34ca206f86921cddf4cd?s=96&d=mm&r=g","caption":"Sandeep Joshi"},"sameAs":["http:\/\/Delveinsight.com"]}]}},"author_meta":{"display_name":"Sandeep Joshi","author_link":"https:\/\/www.delveinsight.com\/blog\/author\/sjoshidelveinsight-com"},"featured_img":"https:\/\/www.delveinsight.com\/blog\/wp-content\/uploads\/2026\/07\/medtech-news-for-polytech-electrowire-neurolexiq-300x187.webp","coauthors":[],"tax_additional":{"categories":{"linked":["<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Notizia - Recent Pharma, Healthcare and Biotech Happenings<\/a>"],"unlinked":["<span class=\"advgb-post-tax-term\">Notizia - Recent Pharma, Healthcare and Biotech Happenings<\/span>"]},"tags":{"linked":["<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">AI In Healthcare<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Alzheimer\u2019s Disease Diagnostic<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Breast Implants<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Diabetic Foot Ulcer Treatment<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Electrophysiology Catheters<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Medical Devices Market<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">MedTech Market<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Spinal Cord Stimulators<\/a>"],"unlinked":["<span class=\"advgb-post-tax-term\">AI In Healthcare<\/span>","<span class=\"advgb-post-tax-term\">Alzheimer\u2019s Disease Diagnostic<\/span>","<span class=\"advgb-post-tax-term\">Breast Implants<\/span>","<span class=\"advgb-post-tax-term\">Diabetic Foot Ulcer Treatment<\/span>","<span class=\"advgb-post-tax-term\">Electrophysiology Catheters<\/span>","<span class=\"advgb-post-tax-term\">Medical Devices Market<\/span>","<span class=\"advgb-post-tax-term\">MedTech Market<\/span>","<span class=\"advgb-post-tax-term\">Spinal Cord Stimulators<\/span>"]}},"comment_count":"0","relative_dates":{"created":"Posted 2 hours ago","modified":"Updated 2 hours ago"},"absolute_dates":{"created":"Posted on Jul 16, 2026","modified":"Updated on Jul 16, 2026"},"absolute_dates_time":{"created":"Posted on Jul 16, 2026 5:29 pm","modified":"Updated on Jul 16, 2026 5:29 pm"},"featured_img_caption":"medtech-news-for-polytech-electrowire-neurolexiq","series_order":"","_links":{"self":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/posts\/35728","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/users\/14"}],"replies":[{"embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/comments?post=35728"}],"version-history":[{"count":1,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/posts\/35728\/revisions"}],"predecessor-version":[{"id":35729,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/posts\/35728\/revisions\/35729"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/media\/35730"}],"wp:attachment":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/media?parent=35728"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/categories?post=35728"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/tags?post=35728"},{"taxonomy":"industry","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/industry?post=35728"},{"taxonomy":"therapeutic_areas","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/therapeutic_areas?post=35728"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}